Syndax’s Targeted Cancer Therapy Induces Remission in Leukemia Patients

Syndax Pharmaceuticals announced that its targeted cancer therapy, SNDX-5613, induced complete remission for certain advanced leukemia patients in an early-stage study.

SNDX-5613 is a highly selective, oral menin inhibitor, a new class of genetically targeted drugs that can potentially treat leukemias which don’t respond to other treatments.

The promising results were seen in certain patients given a higher dose of SNDX-5613 in the phase 1/2 trial that enrolled 43 participants. The preliminary analysis included data from 31 individuals who showed an overall response rate of 48 percent, with 10 patients experiencing complete remission.

The company expects to begin the pivotal phase 2 portion of the trial by the end of the second quarter.